These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9878128)

  • 1. A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome.
    Jansen MJ; Hendriks T; Hermsen R; Van der Meer JW; Goris RJ
    Cytokine; 1998 Nov; 10(11):904-10. PubMed ID: 9878128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice.
    Jansen MJ; Hendriks T; de Man BM; van der Meer JW; Goris RJ
    Cytokine; 1999 Sep; 11(9):713-21. PubMed ID: 10479408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-10 reduces morbidity and mortality in murine multiple organ dysfunction syndrome (MODS).
    Ferrer TJ; Webb JW; Wallace BH; Bridges CD; Palmer HE; Robertson RD; Cone JB
    J Surg Res; 1998 Jul; 77(2):157-64. PubMed ID: 9733603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
    Malleo G; Mazzon E; Genovese T; Di Paola R; Muià C; Caminiti R; Esposito E; Di Bella P; Cuzzocrea S
    Shock; 2008 May; 29(5):560-71. PubMed ID: 17724436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
    Malleo G; Mazzon E; Genovese T; Di Paola R; Caminiti R; Esposito E; Bramanti P; Cuzzocrea S
    Cytokine; 2008 Feb; 41(2):136-43. PubMed ID: 18160304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice.
    Jansen MJ; Hendriks T; Knapen MF; van Kempen LC; van der Meer JW; Goris RJ
    Crit Care Med; 1998 Jul; 26(7):1244-50. PubMed ID: 9671376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrphostin AG-490 inhibited the acute phase of zymosan-induced inflammation.
    Dimitrova P; Ivanovska N
    Int Immunopharmacol; 2008 Nov; 8(11):1567-77. PubMed ID: 18656556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of interleukin-6 in a non-septic shock model induced by zymosan.
    Cuzzocrea S; de Sarro G; Costantino G; Mazzon E; Laurà R; Ciriaco E; de Sarro A; Caputi AP
    Eur Cytokine Netw; 1999 Jun; 10(2):191-203. PubMed ID: 10400825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of peroxisome proliferators-activated receptors (PPAR)alpha enhanced the multiple organ failure induced by zymosan.
    Di Paola R; Esposito E; Mazzon E; Genovese T; Muià C; Crisafulli C; Malleo G; Sessa E; Meli R; Cuzzocrea S
    Shock; 2006 Nov; 26(5):477-84. PubMed ID: 17047518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent improvements in outcome with adenoviral expression of interleukin-10 in a murine model of multisystem organ failure.
    McAuliffe PF; Murday ME; Efron PA; Scumpia PO; Ungaro R; Abouhamze A; Tannahill CL; Hutchins B; LaFace D; Moldawer LL
    Gene Ther; 2006 Feb; 13(3):276-82. PubMed ID: 16251998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of matrix metalloproteinases in the murine zymosan-induced multiple organ dysfunction syndrome.
    Volman TJ; Goris RJ; Lomme RM; DeGroot J; Verhofstad AA; Hendriks T
    J Pathol; 2004 Aug; 203(4):968-75. PubMed ID: 15259001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
    Pallua N; Low JF; von Heimburg D
    Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of selective nitric oxide synthase blocker on survival, mesenteric blood flow and multiple organ failure induced by zymosan.
    Tanriverdi P; Yuksel BC; Rasa K; Guler G; Iskit AB; Guc MO; Korkmaz A
    J Surg Res; 2005 Mar; 124(1):67-73. PubMed ID: 15734481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination immunotherapy which neutralises the effects of TNF alpha and IL-1 beta attenuates the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat.
    Ruetten H; Thiemermann C
    J Physiol Pharmacol; 1997 Dec; 48(4):605-21. PubMed ID: 9444610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome.
    Jansen MJ; Hendriks T; Vogels MT; van der Meer JW; Goris RJ
    Crit Care Med; 1996 Jul; 24(7):1196-202. PubMed ID: 8674335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome.
    Volman TJ; Goris RJ; Hendriks T
    Intensive Care Med; 2005 May; 31(5):701-8. PubMed ID: 15711975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GITR gene deletion and GITR-FC soluble protein administration inhibit multiple organ failure induced by zymosan.
    Galuppo M; Nocentini G; Mazzon E; Ronchetti S; Esposito E; Riccardi L; Di Paola R; Bruscoli S; Riccardi C; Cuzzocrea S
    Shock; 2011 Sep; 36(3):263-71. PubMed ID: 21654556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of L-NG-nitroarginine in a zymosan-induced multiple organ dysfunction syndrome model.
    Ozel H; Yuksel BC; Berkem H; Avsar FM; Guler G; Iskit AB; Guc MO; Hengirmen S
    Eur Surg Res; 2009; 43(2):211-8. PubMed ID: 19556797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of elderly and adult multiple organ dysfunction syndrome in the rat model.
    Zhu Q; Qian X; Wang S; Yin T; Yang J; Xue Q; Xu B
    Exp Gerontol; 2006 Aug; 41(8):771-7. PubMed ID: 16797904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice.
    Jung YO; Cho ML; Lee SY; Oh HJ; Park JS; Park MK; Park MJ; Ju JH; Kim SI; Park SH; Kim HY; Min JK
    Immunol Lett; 2009 Apr; 123(2):138-43. PubMed ID: 19428561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.